The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) increased by $0.6 on Wednesday to $11.39, up 5.56 percent. The last five days have seen an average of 2,394,188 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$11.58. The average number of shares traded over the last 20 days was 2,210,857, while the average volume over the last 50 days totaled 2,198,963.
AUPH stock dropped -7.38% since last month. On 06/14/22, the company’s shares reached a one-month low of $9.18. The stock touched a high of $33.97 on 01/03/22, after rallying from a low of $8.86 in 52 weeks. The price of AUPH stock has declined by -52.82% or -$11.58 this year, reaching a new high 1 time. Still, the stock price is down -66.47% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
There have been 105 days since Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity on Mar 09. On Mar 09, Director MacKay-Dunn R. Hector acquired 5,000 shares at $11.00 each. This transaction resulted in the insider spending $54,985. On Mar 04, MILNE GEORGE M JR added 5,000 shares at a price of US$10.82. After the transaction, the insider now owns 50,000 shares. Ex VP, Intern’l Operations Donley Matthew Maxwell had earlier sold 3,052 shares on Mar 02 for $12.01 a share. The transaction was completed for $36,655.
Beta for the stock is 1.10. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 21.51, the price-to-book (PB) ratio of 3.41.
For the three months ended March 30, Aurinia Pharmaceuticals Inc.’s quick ratio was 13.30, while its current ratio was 14.10, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 98.00% percent. Based on annual data, it had gross profit of $44.51 million and revenue of $45.6 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AUPH’s return on assets (ROA) during the last 12 months has been -37.50%. There was a -37.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -43.20%.
According to Aurinia Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended March 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $21.63 million, while revenues rose by 95.79% to $23.4 million. It was predicted that Aurinia Pharmaceuticals Inc.’s quarterly earnings would be -$0.27, but it ended up being -$0.27. EBITDA was -$35.76 million for the quarter. At the end of Aurinia Pharmaceuticals Inc.’s most recent quarter ended March 30, its liabilities totaled 58.78 million, while its total debt was $8.57 million. Equity owned by shareholders amounts to $141.74 million.
Here’s a quick look at Aurinia Pharmaceuticals Inc.’s (AUPH) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 54.22%, suggesting the stock is Neutral, with a 101.62% historical volatility rate.
The stochastic %K and %D were 40.73% and 34.93% respectively, while the average true range (ATR) was 0.97. Based on the 14-day stochastic reading of 49.94%, the RSI (14) reading is 51.71%. On the 9-day MACD Oscillator, the stock is at 0.25, and the 14-day reading is at -0.20.
Analysts have assigned Aurinia Pharmaceuticals Inc. (AUPH) an Buy rating. AUPH is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.